Caerulein treatment of Parkinson's disease

G. Bruno, S. Ruggieri, T. N. Chase, K. Bakker, C. A. Tamminga

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


In view of evidence linking cholecystokinin-containing neurons with both dopamine system function and Parkinson's disease pathophysiology, the therapeutic effects of the cholecystokinin analog, caerulein, were evaluated in 10 parkinsonian patients stabilized on L-Dopa therapy. Despite substantially elevated plasma caerulein levels immediately following intramuscular injection of this peptide, no consistent change in neurologic status could be discerned. These negative results may be due to the relatively small amounts of caerulein entering the CNS at dose levels that do not induce gastrointestinal toxicity.

Original languageEnglish (US)
Pages (from-to)266-270
Number of pages5
JournalClinical Neuropharmacology
Issue number3
StatePublished - Jan 1 1985

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)


Dive into the research topics of 'Caerulein treatment of Parkinson's disease'. Together they form a unique fingerprint.

Cite this